No data available for drug.
DRUG INTERACTION
No drug interaction found for voriconazole and .
phenobarbital
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
arsenic trioxide
may have an increased QTc-prolonging effect when combined with arsenic trioxide
azithromycin
azithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clozapine
clofazimine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clomipramine
QTc-prolonging agents: they may increase the QTc-prolonging effect of clomipramine
midostaurin
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
olanzapine
olanzapine: they may enhance the QTc-prolonging effect of QTc-prolonging Agents
oxytocin
oxytocin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
mibefradil
QTc-prolongers increase the effect of other QTc-prolonging agents
moexipril
QTc-prolongers increase the effect of other QTc-prolonging agents
voriconazole
QTc-prolongers increase the effect of other QTc-prolonging agents
nelfinavir
QTc-prolongers increase the effect of other QTc-prolonging agents
alfuzosin
QTc-prolongers increase the effect of other QTc-prolonging agents
vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
lenvatinib
QTc interval is increased both by lenvatinib and voriconazole
lorlatinib
the effect of voriconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voriconazole
fedratinib
voriconazole increases the effect of fedratinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
midostaurin
voriconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
neratinib
voriconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
palbociclib
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
ruxolitinib
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
mibefradil
QTc-prolongers increase the effect of other QTc-prolonging agents
moexipril
QTc-prolongers increase the effect of other QTc-prolonging agents
voriconazole
QTc-prolongers increase the effect of other QTc-prolonging agents
nelfinavir
QTc-prolongers increase the effect of other QTc-prolonging agents
alfuzosin
QTc-prolongers increase the effect of other QTc-prolonging agents
citalopram
may have an increased QTc-prolonging effect when combined with citalopram
domperidone
may have an increased QTc-prolonging effect when combined with domperidone
fexinidazole
may increase the QTc-prolonging action of QT-prolonging agents (Highest Risk)
levoketoconazole
may have an increased QTc-prolonging effect when combined with levoketoconazole
sertindole
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
thioridazine
thioridazine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ethinyl estradiol
voriconazole: they may enhance the serum concentration of hormonal contraceptives
ethinylestradiol
voriconazole: they may enhance the serum concentration of hormonal contraceptives
ethynodiol diacetate
voriconazole: they may enhance the serum concentration of hormonal contraceptives
etonogestrel
voriconazole: they may enhance the serum concentration of hormonal contraceptives
asciminib
It may enhance the serum concentration when combined with asciminib
cannabidiol
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
lithium
It may enhance QTc interval when combined with lithium
medroxyprogesterone
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
megestrol
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
mefenamic acid
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
nomegestrol acetate
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
zotepine
may increase the QTc-prolonging effect
maralixibat
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
lenacapavir
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
curcumin
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
glecaprevir
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
caspofungin
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
lumateperone
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
quetiapine
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
lurasidone
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
promethazine
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
mesoridazine
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
diclofenac
voriconazole: they may enhance the serum concentration of diclofenac
paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
methotrexate
methotrexate may increase the photosensitizing effects of methotrexate
trimetrexate
trimetrexate may increase the photosensitizing effects of trimetrexate
brentuximab
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
abemaciclib
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
erlotinib
when both drugs are combined, there may be a reduced metabolism of erlotinib
dienogest
hormonal contraceptives increase the concentration of voriconazole serum
fingolimod
fingolimod may enhance the QTc-prolonging effect of QT-prolonging Agents
lacosamide
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
haloperidol
may enhance the QTc-prolonging effect of haloperidol
brexpiprazole
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
doravirine
it increases by affecting the hepatic enzyme CYP3A4 metabolism
nisoldipine
may enhance the serum concentration of CYP2C9 inhibitors
risperidone
may increase the QTc-prolonging effects of QTc-prolonging agents
fingolimod
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
chloroquine
QT-prolonging Miscellaneous Agents may increase the QTc-prolonging effect of chloroquine
ixazomib
voriconazole, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
amiodarone
QT-prolonging other agents (highest Risk) may intensify amiodarone's QTc-prolonging action
clofazimine
QT-prolonging agents (highest Risk) may increase clofazimine's ability to prolong QTc
No data available for drug.
DRUG INTERACTION
voriconazole
&
No Drug Intearction Found. for voriconazole and .
phenobarbital
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
arsenic trioxide
may have an increased QTc-prolonging effect when combined with arsenic trioxide
azithromycin
azithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clozapine
clofazimine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clomipramine
QTc-prolonging agents: they may increase the QTc-prolonging effect of clomipramine
midostaurin
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
olanzapine
olanzapine: they may enhance the QTc-prolonging effect of QTc-prolonging Agents
oxytocin
oxytocin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
mibefradil
QTc-prolongers increase the effect of other QTc-prolonging agents
moexipril
QTc-prolongers increase the effect of other QTc-prolonging agents
voriconazole
QTc-prolongers increase the effect of other QTc-prolonging agents
nelfinavir
QTc-prolongers increase the effect of other QTc-prolonging agents
alfuzosin
QTc-prolongers increase the effect of other QTc-prolonging agents
vinblastine
when both drugs are combined, there may be a decreased metabolism of vinblastine
lenvatinib
QTc interval is increased both by lenvatinib and voriconazole
lorlatinib
the effect of voriconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voriconazole
fedratinib
voriconazole increases the effect of fedratinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
midostaurin
voriconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
neratinib
voriconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
palbociclib
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
ruxolitinib
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
mibefradil
QTc-prolongers increase the effect of other QTc-prolonging agents
moexipril
QTc-prolongers increase the effect of other QTc-prolonging agents
voriconazole
QTc-prolongers increase the effect of other QTc-prolonging agents
nelfinavir
QTc-prolongers increase the effect of other QTc-prolonging agents
alfuzosin
QTc-prolongers increase the effect of other QTc-prolonging agents
citalopram
may have an increased QTc-prolonging effect when combined with citalopram
domperidone
may have an increased QTc-prolonging effect when combined with domperidone
fexinidazole
may increase the QTc-prolonging action of QT-prolonging agents (Highest Risk)
levoketoconazole
may have an increased QTc-prolonging effect when combined with levoketoconazole
sertindole
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
thioridazine
thioridazine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ethinyl estradiol
voriconazole: they may enhance the serum concentration of hormonal contraceptives
ethinylestradiol
voriconazole: they may enhance the serum concentration of hormonal contraceptives
ethynodiol diacetate
voriconazole: they may enhance the serum concentration of hormonal contraceptives
etonogestrel
voriconazole: they may enhance the serum concentration of hormonal contraceptives
asciminib
It may enhance the serum concentration when combined with asciminib
cannabidiol
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
lithium
It may enhance QTc interval when combined with lithium
medroxyprogesterone
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
megestrol
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
mefenamic acid
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
nomegestrol acetate
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
zotepine
may increase the QTc-prolonging effect
maralixibat
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
lenacapavir
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
curcumin
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
glecaprevir
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
caspofungin
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
lumateperone
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
quetiapine
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
lurasidone
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
promethazine
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
mesoridazine
It could potentially amplify the QTc-prolonging effect of antipsychotic medications known for their QT-prolongation effects
diclofenac
voriconazole: they may enhance the serum concentration of diclofenac
paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
methotrexate
methotrexate may increase the photosensitizing effects of methotrexate
trimetrexate
trimetrexate may increase the photosensitizing effects of trimetrexate
brentuximab
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
abemaciclib
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
erlotinib
when both drugs are combined, there may be a reduced metabolism of erlotinib
dienogest
hormonal contraceptives increase the concentration of voriconazole serum
fingolimod
fingolimod may enhance the QTc-prolonging effect of QT-prolonging Agents
lacosamide
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
haloperidol
may enhance the QTc-prolonging effect of haloperidol
brexpiprazole
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
doravirine
it increases by affecting the hepatic enzyme CYP3A4 metabolism
nisoldipine
may enhance the serum concentration of CYP2C9 inhibitors
risperidone
may increase the QTc-prolonging effects of QTc-prolonging agents
fingolimod
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
chloroquine
QT-prolonging Miscellaneous Agents may increase the QTc-prolonging effect of chloroquine
ixazomib
voriconazole, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
amiodarone
QT-prolonging other agents (highest Risk) may intensify amiodarone's QTc-prolonging action
clofazimine
QT-prolonging agents (highest Risk) may increase clofazimine's ability to prolong QTc
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet